Insmed. has been granted a patent for a method to treat Mycobacterium avium complex lung infections. The method involves aerosolizing a liposomal formulation of amikacin, administered via nebulizer, aiming for negative sputum cultures after at least 84 days of treatment. GlobalData’s report on Insmed gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Insmed, Peptide pharmacophores was a key innovation area identified from patents. Insmed's grant share as of July 2024 was 51%. Grant share is based on the ratio of number of grants to total number of patents.
Aerosolized liposomal amikacin for treating lung infections
The patent US12016873B2 outlines a novel method for treating Mycobacterium avium complex (MAC) lung infections in patients. The method involves administering a pharmaceutical composition containing 560 mg to 590 mg of amikacin, or its pharmaceutically acceptable salt, encapsulated in liposomes. The liposomal formulation includes an electrically neutral phospholipid, specifically dipalmitoylphosphatidylcholine (DPPC), and cholesterol. The treatment is delivered via aerosolization using a nebulizer, allowing for a mixture of free and liposomal amikacin to be inhaled. The regimen requires daily administration for a minimum of 84 days, aiming to achieve at least three consecutive negative MAC sputum cultures, with the first negative culture expected within 28 to 84 days of starting treatment.
Additionally, the patent specifies that the method may be suitable for patients with non-cystic fibrosis lung diseases who have previously not responded to standard MAC therapies. The composition can be supplemented with other therapeutics, including various classes of antibiotics. The treatment protocol emphasizes sustained negative sputum cultures and improvements in lung function, as indicated by metrics such as forced expiratory volume (FEV1) and blood oxygen saturation. The administration period can extend beyond six months, with potential benefits lasting for at least 15 days post-treatment. This innovative approach aims to enhance the efficacy of MAC infection management, particularly for patients with limited treatment options.
To know more about GlobalData’s detailed insights on Insmed, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
